Erleada (Apalutamide): The 2030-2035 Generic Opportunity Window

Johnson & Johnson blockbuster oral second-generation androgen receptor inhibitor Erleada (apalutamide) generated $2.39 billion in full-year 2023 worldwide sales, growing 20% to surpass $2.75 billion in 2024, with U.S. annual net sales exceeding $1.4 billion. Approved under FDA NDA 210951 for non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC) across 60 mg and 240 mg tablet formulations, Erleada remains 100% brand-only in the United States today, with zero generic versions commercially approved or selling. Core drug substance composition-of-matter patent US 8,445,507 expires on September 15, 2030 following a Patent Term Extension granted under 35 U.S.C. 156. Secondary crystalline Form A and Form B polymorph and formulation patents US 9,481,663 and US 10,214,498 extend Orange Book exclusivity through June 4, 2033 and December 23, 2035. Major Indian generic pharmaceutical manufacturers, including Dr. Reddy Laboratories, Sun Pharmaceutical Industries, Lupin, Zydus Lifesciences, and Cipla, maintain active Paragraph IV ANDA filings positioning for commercial entry across the 2030 to 2035 generic opportunity window.